Studies show drug combinations effective for melanoma
Promising new data from trials aimed at delaying resistance to BRAF inhibitors
2012-09-29
(Press-News.org) Vienna, Austria, 29 September 2012 –- Promising new data on drug combinations to treat metastatic melanoma are presented at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.
The phase I and II trials focus on combining drugs to slow the development of resistance to drugs that inhibit BRAF, a gene that is mutated in about half of melanomas. Earlier trials with drugs that target BRAF generated excitement for their ability to quickly shrink melanoma tumors in suitable patients. But for many patients the benefits proved short-lived, as the cancer cells develop resistance to the drugs.
"These studies exemplify an important landmark of some tumors, which has emerged from recent laboratory research: the presence of specific mutations, such as the BRAF mutation in metastatic melanoma which exposes an Achilles' heel--MEK in this case," said Prof Yossef Yarden from the Weizmann Institute of Science, Israel. "In-depth understanding of cancers and their mutations is expected to reveal more of these deadly weaknesses in cancer, which we can exploit using new drugs and drug combinations."
Phase II of the BRAF inhibitor dabrafenib alone vs combination with MEK1/2 inhibitor trametinib
Dr Georgina Long from Westmead Hospital and the Melanoma Institute Australia and colleagues report that combining the new drugs dabrafenib and trametinib provided a clinically meaningful improvement in progression-free survival, response rate and duration of response in 162 patients with melanoma that had BRAF V600 mutations.
Patients in the study received either dabrafenib 150mg twice daily; twice-daily dabrafenib plus once-daily 1mg trametinib; or twice daily dabrafenib plus once-daily 2mg trametinib. The combination prolonged progresion free survival over single-drug therapy from 5.8 months to 9.4 months, which represents a 60% improvement. Among patients who received both drugs at the higher dose, 41% had not progressed 12 months after treatment began, compared to 9% in the monotherapy arm of the study.
"The combination therapy of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib prolongs the progression-free survival in patients with V600 BRAF mutation-positive metastatic melanoma compared with dabrafenic monotherapy," Dr Long said. "Importantly, the combination also decreases the rate of the cutaneous toxicities compared with dabrafenib monotherapy, particularly the oncogenic cutaneous toxicity of squamous cell carcinoma."
Phase IB study of vemurafenib in combination with the MEK inhibitor, GDC-0973
A Phase I study in 44 patients shows that the combination of the MEK inhibitor GDC-0973 and vemurafenib can be delivered safely, Dr Rene Gonzalez of the University of Colorado Cancer Center, Denver, and colleagues report.
"BRAF inhibition has resulted in high response rates and improved survival in patients with BRAF mutated melanoma," Dr Gonzalez said. "One of several mechanisms of resistance has been reactivation of the MAPK pathway. Preclinical models show that combined inhibition of BRAF and MEK can delay the acqusition of resistance compared to BRAF inhibitor monotherapy. Inhibition of the pathway downstream from BRAF with the MEK inhibitor GDC-0973 could theoretically overcome or delay this resistance mechanism and improve outcomes."
The study was not designed to evalate efficacy. "While early data in a small number of patients did show tumor reduction, it would be premature to comment on efficacy based on these preliminary results and further research is warranted," Dr Gonzalez said.
### END
ELSE PRESS RELEASES FROM THIS DATE:
2012-09-29
VIENNA, Austria, 29 September 2012 –- New trial data showing improvements in the treatment of esophageal and gastrointestinal cancers were released today at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.
Phase III, randomized, double-blind, placebo-controlled trial of gefitinib versus placebo in esophageal cancer progressing after chemotherapy
The first phase III trial to address the need for second-line treatments in esophageal cancer shows that gefitinib improves important quality-of-life measures and extends progression-free survival, ...
2012-09-29
Vienna, Austria, 29 September 2012 –- Governments around the world are leaving hundreds of millions of cancer patients to suffer needlessly because of their failure to ensure adequate access to pain-relieving drugs, an unprecedented new international survey reveals.
The new data, released to the public during the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna, paints a shocking picture of unnecessary pain on a global scale, said Prof Nathan Cherny, lead author of the report from Shaare Zedek Medical Center, Jerusalem, Israel, Chair of the ESMO ...
2012-09-29
Combined treatment with two drugs targeting different points in the same growth-factor pathway delayed the development of treatment resistance in patients with BRAF-positive metastatic malignant melanoma. The results of a phase I/II study of treatment with the kinase inhibitors dabrafenib and trametinib will be published in the New England Journal of Medicine and are being released online to coincide with a presentation at the European Society for Medical Oncology meeting in Vienna.
"We investigated this combination because of research we and others have conducted ...
2012-09-29
NARRAGANSETT, R.I. – September 28, 2012 – Scientists at the University of Rhode Island's Graduate School of Oceanography have made the first observation of a predator avoidance behavior by a species of phytoplankton, a microscopic marine plant. Susanne Menden-Deuer, associate professor of oceanography, and doctoral student Elizabeth Harvey made the unexpected observation while studying the interactions between phytoplankton and zooplankton.
Their discovery will be published in the September 28 issue of the journal PLOS ONE.
"It has been well observed that phytoplankton ...
2012-09-29
The apple flea weevil, a sporadic insect pest in the early 1900s, has reemerged as a severe pest in organic apple orchards in Michigan, where outbreak population levels have been observed since 2008, and damage has resulted in up to 90% losses for apple growers.
According to the authors of "The Reemergence of an Old Pest, Orchestes pallicornis (Coleoptera: Curculionidae)," an open-access article appearing in the lastest issue of the Journal of Integrated Pest Management, the weevil can be managed by broad-spectrum insecticides used in conventional agriculture, but there ...
2012-09-29
(SACRAMENTO, Calif.) — UC Davis investigators have found new evidence that a promising type of stem cell now being considered for a variety of disease therapies is very similar to the type of cells that give rise to cancer. The findings suggest that although the cells -- known as induced pluripotent stem cells (iPSCs) -- show substantial promise as a source of replacement cells and tissues to treat injuries, disease and chronic conditions, scientists and physicians must move cautiously with any clinical use because iPSCs could also cause malignant cancer.
The article, ...
2012-09-29
CHAMPAIGN, Ill. — University of Illinois researchers have a new low-cost method to carve delicate features onto semiconductor wafers using light – and watch as it happens.
"You can use light to image the topography and you can use light to sculpture the topography," said electrical and computer engineering professor Gabriel Popescu. "It could change the future of semiconductor etching."
Chip makers and semiconductor researchers need to very precisely control the dimensions of their devices. The dimensions of the components affect performance, speed, error rate and time ...
2012-09-29
Tadpole shrimp are pests of rice production systems in California and have recently been found impacting Missouri and Arkansas rice fields. The shrimp feed on rice seedlings and uproot them during foraging, and their foraging behavior causes water to become muddy, which reduces light penetration to submerged seedlings and delays the development of the rice plant.
In "Review of a New Pest of Rice, Tadpole Shrimp (Notostraca: Triopsidae), in the Midsouthern United States and a Winter Scouting Method of Rice Fields for Preplanting Detection," a new open-access article appearing ...
2012-09-29
This gives new meaning to the complaint "I'm bored" — literally.
Canadian researchers — including a professor from the University of Guelph — have come up with a new, precise definition of boredom based on the mental processes that underlie the condition.
Although many people may see boredom as trivial and temporary, it actually is linked to a range of psychological, social and health problems, says Guelph psychology professor Mark Fenske. He's among authors of a new study in Perspectives on Psychological Science, published by the Association for Psychological Science.
Boredom ...
2012-09-29
Millions of pounds of unexploded bombs and other military ordnance that were dumped decades ago in the Gulf of Mexico, as well as off the coasts of both the Atlantic and Pacific oceans, could now pose serious threats to shipping lanes and the 4,000 oil and gas rigs in the Gulf, warns two Texas A&M University oceanographers.
William Bryant and Neil Slowey, professors of oceanography who have more than 90 years of combined research experience in all of the Earth's oceans, along with fellow researcher Mike Kemp of Washington, D.C., say millions of pounds of bombs are scattered ...
LAST 30 PRESS RELEASES:
[Press-News.org] Studies show drug combinations effective for melanoma
Promising new data from trials aimed at delaying resistance to BRAF inhibitors
